Some strategies seek to alter molecular mechanisms that can redirect the programmed death of tumor cells. If you can’t selectively eliminate them or stop their proliferation, ask them to die, but don’t tell any other cells. That is the idea proposed by a group of researchers participating in a Chinese-American collaboration for the design of the new drug N6F11. In a mouse model, the compound caused death by ferroptosis only of cancer cells without altering immune cells. Read More
Researchers from Genequantum Healthcare (Suzhou) Co. Ltd. have presented the first preclinical data on GQ-1007, an antibody immune agonist conjugate (AIAC) targeting HER2, for the treatment of cancer. GQ-1007 is an anti-HER2 antibody conjugated via Genequantum’s highly stable linker and enzymatic conjugation technology to a Toll-like receptor 7/8 (TLR7/8) agonist. Read More
The DDX39B gene belongs to the DExD/H-box family of ATP-dependent RNA helicases, playing a vital role in mRNA processing. DDX39B is a component of the TRanscription-EXport (TREX) protein complex, whose pathogenic variants have been recently associated with neurodevelopmental and neurodegenerative disorders. Read More
Cancer Research UK and the KWF Dutch Cancer Society (KWF) have established a new multi-project strategic partnership to advance promising therapeutic agents for cancer. Read More
Merck KGaA scientists have identified new pyrido[3,2-d]pyrimidines acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors. Read More
Evotec SE and Dewpoint Therapeutics Inc. have established a strategic R&D collaboration to advance Dewpoint’s oncology pipeline programs of condensate modifying therapeutics to IND application stage. Read More
Enanta Pharmaceuticals Inc. has patented heterocyclic compounds potentially useful for the treatment of metapneumovirus (MPV), influenza and respiratory syncytial virus (RSV) infections. Read More
Substituted fluorinated N-propyl-pyrrolidine and n-propyl-azetidine compounds acting as estrogen receptor (ER) antagonists and selective estrogen receptor degradation (SERD) inducers have been reported in a Sanofi SA patent. Read More
At the recent American Society of Human Genetics meeting, researchers from Stanford University reported clinical and functional evidence of the involvement of ARHGAP1, a Rho GTPase-activating protein (GAP) gene, in a patient exhibiting a syndromic neurodevelopmental disorder. Read More
Myeloid cells expressing LILRB2 are abundant in the tumor microenvironment and can both drive cancer progression and hinder immune responses. Thus, targeting LILRB2 offers a potential strategy to boost immune-based cancer therapies, as it counteracts their suppressive effects on pro-inflammatory pathways. Read More
